Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Statera Biopharma Inc STAB

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.


GREY:STAB - Post by User

Bullboard Posts
Post by DallasTauruson Jun 05, 2007 10:44pm
96 Views
Post# 12897830

Gov''t Contracting May be a Key

Gov''t Contracting May be a KeyGovernment Contracting May be One Avenue of Success for CBLI Over the last couple of days, the shares have been quietly moving upward, as the Company Continues its Important Work The Analyst with WBB Securities indicated that the potential for Government Contracting Awards is a viable one. He indicated that the potential of Government Contract Awards played a partial role in his evaluation of CBLI. If the Company is successful in that area, the financial impact can be large. The Company’s pre-clinical studies appear to make sense. They have shown their ability to meet un-met needs in the fields of radiation protection, as well as transplantation protocols specific to regenerative stem cell transplant therapy.
Bullboard Posts